Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00757029

Acronym

NETADHD

Enrollment

150

Registered

2008-09-22

Start date

2005-10-31

Completion date

2010-08-31

Last updated

2011-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder With Hyperactivity, Methylphenidate, Pharmacogenetics

Keywords

ADHD,, norepinephrine transporter, pharmacogenetics

Brief summary

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Interventions

GENETICnorepinephrine transporter polymorphism,

OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* ADHD * Physically healthy

Exclusion criteria

* Neurological illness * Concurrent additional psychiatric treatment * \< IQ 70 * Psychotic disorder * Major mood disorder needed other psychiatric medication * Significant suicidal ideation * Pervasive developmental disorder

Design outcomes

Primary

Measure	Time frame
Korean ADHD Rating scale-parent version (KARS)	baseline,1,2,4,8 weeks

Secondary

Measure	Time frame
Barkely side effect rating scale	1,2,4,8weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026